免疫疗法
癌症
医学
癌症免疫疗法
免疫系统
细胞因子
细胞毒性T细胞
癌症研究
白细胞介素15
免疫学
白细胞介素
生物
内科学
体外
生物化学
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2017-05-02
卷期号:17 (8)
被引量:78
标识
DOI:10.2174/1568009617666170427102729
摘要
Background: Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably. Methods: In this review, we describe the structural features of IL-12 family and their roles involved in cancer. Results: IL-12 has been demonstrated to regulate both innate (natural killer cells) and adaptive (cytotoxic T lymphocytes) immunities in cancer therapy. This cytokine has been proposed as a potential new agent to be developed in cancer immunotherapy studies due to its impressive antitumor effects in many animal models. In addition, the antitumor activity of IL-12 can be efficiently induced by itself as well as significantly improved by its combination with various treatment modalities including antibodies, antiangiogenic agents, radiotherapy, adoptive therapy, and anti-tumor vaccines. Conclusion: IL-12 has potential roles in anticancer therapy. The advantages of using immunotherapeutic approaches in clinical trials have been reported recently. However, the mechanisms to underlay the immunoregulation and antitumor activities of IL-12 itself, as well as its combination, remain under investigation. Keywords: IL-12, NK cells, cancer, Th1 pathway, receptor, immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI